Patients usually arrive having heard a brand name from a friend, a podcast, or an advertisement. That is a reasonable starting point, but these two medications are not interchangeable, and choosing between them is a clinical decision rather than a preference.
The Mechanical Difference
Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone your body already produces after eating — one that slows gastric emptying, signals fullness to the brain, and supports insulin release when glucose is elevated.
Tirzepatide acts on the GLP-1 receptor as well, but adds activity at a second receptor, GIP. GIP is another incretin hormone involved in insulin response and fat metabolism. The practical result of engaging both pathways has been, in head-to-head trial data, greater average weight reduction.
Why Greater Average Loss Isn't Automatically the Answer
Averages describe populations. The person in the room is one data point. Several things shape the actual choice:
- ToleranceSome patients handle one considerably better than the other.
- Existing conditionsDiabetes, cardiovascular history, gastrointestinal issues and prior surgery all factor in.
- Cost and coverageThe medication you can sustain beats the one you stop after two months.
- GoalsThe target amount of loss changes the calculus.
- SupplyAvailability has been an unpredictable variable in this category.
What Both Require
Neither is a standalone solution. Both work best inside a program that protects muscle, supplies adequate protein, and addresses the hormonal and metabolic drivers underneath the weight — insulin resistance, thyroid function, sleep, cortisol. Without that, you are treating appetite and leaving the machinery untouched.
A Note on Sourcing
The regulatory landscape around compounded versions has shifted significantly. Whatever you take should come through a legitimate, supervised channel with real oversight.
Find the Right Fit
book a consultation to discuss which is appropriate for you, or read more about medical weight management.